The company has had space in the complex since its 2012 acquisition of Human Genome Sciences. International drug giant GSK PLC is moving its vaccine R&D and infectious disease teams from Rockville ...

GSK (NYSE:GSK) finalized the deal to acquire Boston-based, clinical-stage biopharmaceutical company—IDRx for a total of up to $1.15 billion cash consideration. Under the agreement signed by both ...

GSK is relocating to a property in the Boston area, a major life sciences hub. The departure of GSK leaves GI Partners, the property owner, in a potentially difficult financial situation as they ...

GSK plc announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment ...

He is the second recent recruit to the team after Jeremy England, senior director of AI and machine learning, who is a former physics professor at MIT and will be based in Boston. GSK’s entire ...

International biotechnology company GlaxoSmithKline is moving its vaccine and infectious disease research teams to Cambridge, in a latest step to strengthen its presence in the Greater Boston area ...

GSK (GSK) plc announced that it has completed the acquisition of IDRx, Inc., a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the ...

"The proposed acquisition further strengthens our vaccines R&D pipeline, provides access to a new, potentially disruptive technology, and broadens GSK's existing scientific footprint in the Boston ...

F. Hoffmann-La Roche, one of the world’s largest biotechnology companies, announced on Thursday that it will establish an ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it revealed (PDF) that Walmsley took a 16% pay cut in 2024, it also laid out a new compensation ...